Biotech firm VERAXA starts trading on Nasdaq
生物科技公司 VERAXA 在納斯達克上市交易
更新於: 2026年6月11日 下午12:35
On June 11, 2026, Zurich-based VERAXA Biotech AG officially entered the public market, beginning trade on the Nasdaq Capital Market under the ticker symbol 'VRXA'.
2026年6月11日，總部設於蘇黎世的VERAXA Biotech AG正式進入公開市場，以股票代號「VRXA」在納斯達克資本市場開始交易。
Although the merger process began in April 2025, the final transition to public status faced significant hurdles; nearly all of Voyager's shareholders opted to redeem their shares, resulting in limited cash flow from the SPAC trust.
進行企業合併所達成。
VERAXA, which originated from research at the European Molecular Biology Laboratory, specializes in oncology.
儘管合併程序始於2025年4月，但最終轉型為上市公司的過程面臨重大障礙；Voyager近乎所有的股東都選擇贖回其股份，導致來自SPAC信託基金的現金流非常有限。
Their proprietary BiTAC technology acts as a biological 'AND gate,' ensuring that immune responses are triggered only when two tumor markers are present.
源自歐洲分子生物實驗室(EMBL)研究的VERAXA專精於腫瘤學。
This approach aims to maximize the destruction of solid tumors while sparing healthy tissue.
其專有的BiTAC技術扮演著生物學上的「及閘」(AND gate)角色，確保僅在偵測到兩個腫瘤標記時才啟發免疫反應。
As a pre-commercial firm, VERAXA is currently focused on advancing its antibody-based therapeutics, including bispecific T-cell engagers and antibody-drug conjugates.
此方法旨在最大限度地破壞實體腫瘤，同時保護健康組織。
Having secured additional funding through note financing and share purchase agreements, the company now faces the critical challenge of navigating clinical trials to prove the efficacy of its innovative pipeline.
作為一家尚未商業化的公司，VERAXA目前專注於推進其以抗體為基礎的治療法，包括雙特異性T細胞銜接器與抗體藥物偶聯物。
